Guardant Health, Inc. (NASDAQ: GH) is one of the 20 Best Performing Stocks in 2025 according to Insider Monkey. Guggenheim analyst Subbu Nambi raised the price target for GH from $85 to $115 with a buy rating, citing recent updates and discussions with management teams. Canaccord also maintained a Buy recommendation on GH with a price target of $125, expecting sector momentum to continue in 2026. Guardant Health, Inc. specializes in liquid-based cancer testing for clinical and research purposes.

Read more at Yahoo Finance: Guggenheim Analyst is Bullish on Guardant Health, Inc. (GH)